Cellectis (CLLS) Net Cash Flow Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 32.17% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -46.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.54% |
| Sep 30, 2025 | 32.69% |
| Jun 30, 2025 | -45.06% |
| Mar 31, 2025 | -85.49% |
| Sep 30, 2024 | 32.69% |
| Jun 30, 2024 | -15.60% |
| Mar 31, 2024 | -130.40% |
| Dec 31, 2023 | 103.28% |
| Sep 30, 2023 | -32.27% |
| Jun 30, 2023 | 66.95% |
| Mar 31, 2023 | 44.42% |
| Sep 30, 2022 | 14.87% |
| Jun 30, 2022 | 4.14% |
| Mar 31, 2022 | 28.83% |
| Sep 30, 2021 | -107.46% |
| Jun 30, 2021 | -44.67% |
| Mar 31, 2021 | 59.87% |
| Dec 31, 2020 | -7.12% |
| Sep 30, 2020 | -30.60% |
| Jun 30, 2020 | 2.24% |
| Mar 31, 2020 | -37.56% |
| Dec 31, 2019 | -30.47% |
| Sep 30, 2019 | -111.74% |
| Jun 30, 2019 | -16.05% |
| Mar 31, 2019 | 38.99% |
| Dec 31, 2018 | -40.05% |
| Sep 30, 2018 | 45.78% |
| Jun 30, 2018 | 7.04% |
| Mar 31, 2018 | -57.58% |